Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. ("Dare") on March 31, 2022. The filing discloses the entry into a material definitive agreement with Organon International GmbH, an affiliate of Organon & Co., regarding the commercialization of Dare's product XACIATO (clindamycin phosphate vaginal gel, 2%).
Key Financial Metrics and Transaction Terms
The filing details a licensing agreement with the following financial components:
- Upfront Payment: $10.0 million non-refundable and non-creditable payment to Dare upon the effective date of the agreement.
- Milestone Payments: Up to $182.5 million in total potential milestones, including:
- $2.5 million upon the first commercial sale in the United States (expected Q4 2022).
- Up to $180.0 million in tiered commercial sales and regulatory milestones.
- Royalties: Tiered double-digit royalties based on net sales.
- Interim Supply: Organon will purchase XACIATO from Dare at a transfer price equal to Dare's manufacturing costs plus a single-digit percentage markup until Organon assumes supply responsibilities.
The filing does not provide Dare's current revenue, profit, cash flow, or debt levels as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Outlook
The primary material change is the strategic partnership to commercialize XACIATO, which received FDA approval in December 2021 for the treatment of bacterial vaginosis. Under the agreement, Organon obtains exclusive worldwide rights to develop, manufacture, and commercialize XACIATO and future intravaginal or urological products formulated with clindamycin relying on Dare's IP.
Management commentary indicates that the first commercial sale of XACIATO in the U.S. is expected during the fourth quarter of 2022. The agreement is subject to closing conditions, including antitrust approvals under the Hart-Scott-Rodino Act.
Risks and Contingencies
The filing highlights several risks and contingencies:
- Closing Conditions: The agreement is not yet effective and depends on the satisfaction of closing conditions, including antitrust approvals.
- Termination Rights: Organon may terminate the agreement in its entirety or on a country-by-country basis at its sole discretion with 120 days' written notice following the first anniversary of the effective date.
- Operational Dependence: Dare relies on Organon for commercialization and third parties for supply, lacking control over their efforts and resources.
- Payment Uncertainty: Actual payments may be significantly less than anticipated if milestones are not met or if the agreement is terminated early.
Investor Verification Checklist
- Verify the satisfaction of antitrust closing conditions required for the agreement to become effective.
- Monitor the timeline for the first commercial sale of XACIATO in the U.S. to confirm the $2.5 million milestone trigger.
- Review the upcoming Form 10-Q for the quarter ended March 31, 2022, for the full text of the agreement and Dare's updated financial position.
- Assess the impact of the interim supply arrangement (cost-plus markup) on Dare's near-term revenue recognition.